Cure My Disease

Don't miss your cure!

 Log in / Sign up

New virus therapy takes on tough bladder cancer

NCT ID NCT07283835

Recruiting now Disease control Sponsor: Lepu Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a treatment called cretostimogene grenadenorepvec, a modified virus designed to infect and destroy cancer cells, in 16 people with high-risk bladder cancer that has not responded to standard BCG therapy. The study aims to see if the treatment can make tumors disappear and how long that effect lasts. Participants receive the virus directly into the bladder, along with a helper substance to improve its action.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cretostimogene grenadenorepvec (a modified virus that targets and kills cancer cells)
What this could lead to
If it works, this could offer a new treatment option for people with bladder cancer that has not responded to standard therapy, potentially delaying or avoiding the need for bladder removal.
What could go wrong
This is a small, early-phase trial with only 16 participants, so results may not apply to everyone. The treatment may cause side effects or fail to control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCG-UNRESPONSIVE HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder carcinoma in situ bladder papillary urothelial carcinoma in situ carcinoma non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH-GRADE TA/ T1 PAPILLARY DISEASE BLADDER CANCER NON-MUSCLE INVASIVE BLADDER CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Chongqing University Cancer Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, 400030, China

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350014, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, 410013, China

  • Peking University First Hospital (First Clinical Medical School of Peking University)

    RECRUITING

    Beijing, Beijing Municipality, 100034, China

  • Qilu Hospital of Shandong University

    RECRUITING

    Jinan, Shandong, 250012, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

  • The Affiliated Drum Tower Hospital of Nanjing University Medical School

    RECRUITING

    Nanjing, Jiangsu, 210008, China

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, 325000, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

  • The First Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110001, China

  • The Second Hospital of Tianjin Medical University

    RECRUITING

    Tianjin, Tianjin Municipality, 300211, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430022, China

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.